

The Executive Board of DataWalk S.A., with its registered seat in Wrocław, Poland (“Company”, “Issuer”), reports estimated selected financial data for the Data Walk Capital Group (“Group”) for the first half of 2026, together with comparable data.

Selected consolidated financial data for the first half of 2026 and the comparable period (in thousands of PLN).

	H1'2026	H1'2025	Change	Change (%)
Revenue	11 042	23 765	-12 723	-54%
Cost of revenue	2 929	3 929	-1 000	-25%
Gross profit (loss) from sales	8 113	19 836	-11 723	-59%
Operating profit (loss) / EBIT	-40 066	-60 407	20 341	-34%
EBIT adjustment for significant non-cash items, including:	17 385	58 257	-40 872	-70%
- <i>depreciation</i>	2 385	1 829	556	30%
- <i>incentive program</i>	15 101	54 980	-39 879	-73%
- <i>impairment losses on assets</i>	-101	1 448	-1 549	-
EBITDA adjusted	-22 681	-2 150	-20 531	955%

The Executive Board decided to present an additional financial metric - EBITDA adjusted for the costs of the incentive program and the change in asset impairment allowances when presenting estimated data, due to the fact that these items are non-cash in nature and do not affect the current financial position (in particular, liquidity) of the Issuer and the Group.

The most significant impact on the change in the Group's consolidated EBITDA adjusted in the first half of 2026 was driven by:

a) Revenue drivers:

- a decrease in license revenues (recognized point-in-time) by PLN 13 122 thousand, i.e., by 81% compared to the prior-year period;
- an increase in service revenues (recognized over time) by PLN 398 thousand, i.e., by 5% compared to the prior-year period.

b) Business growth and scaling investments (OPEX):

- an increase in Sales & Marketing expenditures (Go-To-Market) by PLN 3 478 thousand, i.e., by 43% compared to the prior-year period;
- an increase in R&D expenditures across product development and Field Engineering by PLN 2 475 thousand, i.e., by 19% compared to the prior-year period.

c) Accounting effects (Non-cash):

- a change in the accounting treatment of R&D expenditures, resulting in a negative impact on EBITDA in the amount of PLN 1 505 thousand, caused by the cessation of capitalization of DataWalk 5.0.0 development costs (IAS 38) and their full recognition as current period expenses following the release date.